Humoral immunity and transcriptome differences of COVID-19 inactivated vacciane and protein subunit vaccine as third booster dose in humanArticle Published on 2022-10-212022-11-16 Journal: Frontiers in Immunology [Category] 변종, 유전자 메커니즘, [키워드] analyzed antibody approach booster booster dose caused correlation COVID-19 differentially expressed gene dose effective Effectiveness Efficacy Factor Health help Heterologous homologous humoral humoral immune response Humoral immunity immune Immune escape immune response Immunity immunization inactivated Inactivated vaccine indicated innate immune function innate immune pathways participant Perspective Prevalence protein subunit vaccine provided significantly Support System third booster vaccine transcriptional response Transcriptome transcriptome analysis transcriptomic analysis vaccination Vaccine variants of concern VOCs with COVID-19 [DOI] 10.3389/fimmu.2022.1027180 PMC 바로가기
Immunogenicity and reactogenicity of a third dose of BNT162b2 vaccine for COVID-19 after a primary regimen with BBIBP-CorV or BNT162b2 vaccines in Lima, PeruArticle Published on 2022-10-172022-11-15 Journal: PLoS ONE [Category] 진단, [키워드] administration ANCOVA anti-SARS-CoV-2 IgG antibody BBIBP-CorV BNT162b2 BNT162b2 vaccine booster conducted COVID-19 infection COVID-19 vaccine dose Elderly patient evaluated geometric geometric mean ratio HCW healthcare worker Heterologous heterologous vaccine homologous IgG IgG antibody IgG level immunized immunogenic immunogenicity increase in median mRNA vaccine National of BNT162b2 participant Pfizer produced prospective cohort study reactogenic reactogenicity regimen regressions Safe significantly Sinopharm two group vaccination Vaccine vaccine for COVID-19 was measured [DOI] 10.1371/journal.pone.0268419 PMC 바로가기
Safety and immunogenicity of intradermal administration of fractional dose CoronaVac®, ChAdOx1 nCoV-19 and BNT162b2 as primary series vaccinationArticle Published on 2022-10-042022-11-15 Journal: Frontiers in Immunology [Category] COVID19(2023년), SARS, 변종, 진단, 치료기술, [키워드] administration Adverse adverse effect anti-RBD Anti-RBD IgG antibody Antibody Response Arm ARMS binding domain BNT162b2 ChAdOx1 ChAdOx1 nCoV-19 comparable Concentration conducted CoronaVac country COVID COVID vaccine COVID-19 COVID-19 vaccine COVID-19 vaccines dose Effect Effects eligible exploratory first dose fractional dose vaccination Frame Heterologous heterologous regimen highest homologous IgG immunogenic implication IMPROVE Intradermal intradermal vaccination intradermal vaccine intramuscular intramuscular vaccination less lowest of BNT162b2 Omicron variant pilot study Population Protein regimen regimens reported Safe Safety SARS-CoV-2 variants second dose spike Standard dose Study participants systemic adverse reaction T-cell Response the SARS-CoV-2 undetectable vaccination Vaccine vaccine immunogenicity vaccine safety [DOI] 10.3389/fimmu.2022.1010835 PMC 바로가기
Heterologous gam-COVID-vac (sputnik V)/mRNA-1273 (moderna) vaccination induces a stronger humoral response than homologous sputnik V in a real-world data analysisArticle Published on 2022-10-012022-11-15 Journal: Clinical microbiology and infection : the official [Category] COVID19(2023년), SARS, 진단, [키워드] adjusted adverse effect age Analysis Anti-spike binding antibody unit binding domain boost Combination Complete Concentration COVID COVID-19 doses enrolled evaluated event female Frequency Gam-COVID-Vac Gender Heterologous Heterologous scheme homologous humoral humoral immune response IgG immunization increase individual induce interquartile range IQR Linear model median Mild moderate Moderna mRNA-1273 participant RBD real-world data required SARS-CoV-2 Serological assay Seven significantly significantly higher vaccination Vaccine [DOI] 10.1016/j.cmi.2022.05.009 PMC 바로가기
Heterologous ChAdOx1 and Bnt162b2 vaccination induces strong neutralizing antibody responses against SARS-CoV-2 including delta variant with tolerable reactogenicityArticle Published on 2022-10-012022-11-15 Journal: Clinical microbiology and infection : the official [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] anti-receptor-binding domain antibody Antibody titer binding antibody BNT162b2 booster dose ChAdOx1 comparable COVID-19 delta variant domain dose enrolled evaluated geometric geometric mean titer group groups HCW HCWs healthcare worker Heterologous heterologous vaccination homologous humoral immune response Humoral response immunogenicity induce Local Neutralizing antibody response Neutralizing antibody titer participant RBD reactogenicity reactogenicity profile reduced robust SARS-CoV-2 SARS-CoV-2 spike protein significantly higher systemic reactogenicity tolerable vaccination variant wild-type SARS-CoV-2 [DOI] 10.1016/j.cmi.2022.04.019 PMC 바로가기
Heterologous adenovirus-vector/messenger RNA regimen is associated with improved severe acute respiratory syndrome coronavirus 2 humoral response in liver transplant recipientsArticle Published on 2022-10-012022-11-15 Journal: Hepatology communications [Category] COVID19(2023년), SARS, 진단, [키워드] 95% CI 95% confidence interval acute respiratory syndrome Analysis analyzed Anti-spike anti-Spike IgG Antibody Response AstraZeneca BBIBP-CorV BMI booster response ChAdOx1 Clinical data collected Combination Concentration Control coronavirus correlation different dose dose evaluate evaluated Future groups healthy volunteer Heterologous homologous humoral IgG immunized Immunoglobulin inactivated information liver LTR LTRs Messenger RNA MMF neutralizing antibody nucleocapsid protein Odds ratio positive positive serology Probability prospective cohort study R 2 receiving recipient reduced reduction regimen reported RNA SARS-CoV-2 SARS-CoV-2 anti-spike IgG Serious Adverse Event Side effects significant difference significantly significantly higher Sinopharm Vaccine vaccine dose vaccine platform [DOI] 10.1002/hep4.2034 PMC 바로가기
Full seroconversion in initial non-responders with higher antibody levels after heterologous COVID-19 vaccination scheduleArticle Published on 2022-10-012022-11-15 Journal: Immunology letters [Category] COVID19(2023년), SARS, 변종, 진단, 치료기술, [키워드] analyzed antibody Antibody testing ChAdOx1 vector vaccine circulating COVID-19 COVID-19 vaccination COVID-19 vaccine cross-reactive antibody detectable dose ENhance first dose Heterologous Heterologous COVID-19 vaccine schedule homologous humoral immune response IgG titer immune individual initial Initial non/low responder neutralization titer neutralizing antibody non-responder positive Retrospective study SARS-CoV-2 strain second dose Seroconversion Vaccination strategy vaccine dose vaccinee variants of concern [DOI] 10.1016/j.imlet.2022.09.001 PMC 바로가기
Immunogenicity After a Heterologous BNT262b2 Versus Homologous Booster in Kidney Transplant Recipients Receiving 2 Doses of CoronaVac Vaccine: A Prospective Cohort StudyArticle Published on 2022-10-012022-11-15 Journal: Transplantation [Category] 진단, [키워드] acute respiratory syndrome antibody Antibody Response Antibody titer BNT162b2 mRNA booster cohort study Comparative confounding variables CoronaVac coronavirus coronavirus disease COVID-19 dose groups Heterologous homologous immunogenicity Immunoglobulin Immunoglobulin G indicate kidney transplant recipient mRNA vaccine Neutralizing Neutralizing antibodies neutralizing antibody Older Patient produced proportion Prospective recipient remained resulting Seroconversion seroconversion rate seronegative seronegative patient seropositive single-center Transplant Vaccine [DOI] 10.1097/TP.0000000000004260 PMC 바로가기
Antibody response after two doses of homologous or heterologous SARS-CoV-2 vaccines in healthcare workers at health promotion centers: A prospective observational study건강증진센터 의료 종사자를 대상으로 동종 또는 이종 SARS-CoV-2 백신 2회 접종 후 항체 반응: 전향적 관찰 연구Observational Study Published on 2022-10-012022-09-12 Journal: Journal of medical virology [Category] COVID19(2023년), MERS, SARS, 임상, 진단, [키워드] Abbott Diagnostics acute respiratory syndrome affecting anti-SARS-CoV-2 anti-spike-protein receptor-binding domain (S-RBD) antibodies antibody chemiluminescence coronavirus coronavirus disease COVID-19 determine domain dose Factor female first dose HCW HCWs Health healthcare healthcare worker Healthcare workers Heterologous highest homologous homologous or heterologous identify IgG level immune immunoassay individuals Linear regression analysis Messenger RNA Microparticle mRNA mRNA vaccine mRNA vaccines multivariable participant prospective observational study recruited S-RBD SARS-CoV-2 SARS-CoV-2 antibody SARS-CoV-2 IgG SARS-CoV-2 vaccine second dose severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines Sex significantly significantly higher tested the antibody response vaccination Vaccine Viral vector vaccine Viral vector vaccines were measured [DOI] 10.1002/jmv.27911 PMC 바로가기 [Article Type] Observational Study
Immunological study of COVID-19 vaccine candidate based on recombinant spike trimer protein from different SARS-CoV-2 variants of concernArticle Published on 2022-09-292022-11-15 Journal: Frontiers in Immunology [Category] SARS, 변종, 진단, [키워드] addition AstraZeneca Beta booster booster dose CD4 CD4+ CD8+ central memory ChAdOx1 Concentration COVID-19 COVID-19 vaccine Delta evaluated follicular highest homologous IFN-gamma IgG IgG antibody IgG isotype IL-17 Immune escape immunogenic immunogenicity induce memory mice mice immunization neutralizing antibody Neutralizing antibody titer new SARS-CoV-2 performed Population populations Protein S protein SARS-CoV-2 SARS-CoV-2 S protein SARS-CoV-2 variant SARS-CoV-2 variants significantly higher spike trimer spike trimeric protein T cells tested trimeric Trimeric spike protein Vaccine vaccine candidate Vaccines variant variants viral variant virus viruses VoC Wuhan [DOI] 10.3389/fimmu.2022.1020159 PMC 바로가기